The University of Southern California and Amgen have teamed up to provide researchers access to two of Thermo Fisher Scientific’s cryo-EM instruments.
The University of Southern California (USC) and Amgen have formed a partnership through which they can provide researchers access to two Thermo Fisher Scientific cryo-transmission electron microscopes (cry-TEMs): the Krios and Glacios cryo-TEMs. The partnership aims to accelerate the pace of research and discovery.
The instruments, housed at the Michelson Center for Convergent Bioscience at USC’s University Park Campus, offer built-in connectivity that will enable researchers from both institutions to increase disease-research productivity. With the two instruments as part of their workflow, the researchers will be able to pre-screen samples at moderate resolutions on the Glacios, after which they can transfer the best-quality samples for imaging at the highest resolutions on the Krios, Thermo Fisher announced in an Aug. 10, 2021 press release.
Amgen will use the instruments to accelerate drug discovery through three techniques:
Under the partnership, USC will provide instrument expertise to Amgen as USC advances its own research. For example, researchers plan to use Krios and Glacios to complete development of an atomic-level map of the human cell, a prominent project for the university. The USC researchers will also continue their work in observing proteins in a wide range of conformational states, similar to what another team of USC researchers recently accomplished with the human neurotransmitter receptor GABA-B.
“We anticipate this equipment will contribute to Amgen’s better understanding of disease mechanisms as we analyze drug targets. With the ability to view drug targets in their near-native states at the atomic level, our hope is to bring more speed and power to drug discovery,” said Philip Tagari, vice-president of Therapeutic Discovery at Amgen, in the press release.
“Housing these instruments in USC’s new Center for Nanoimaging will drive fundamental research underpinning advances in human health across our campuses. We believe it will help us continue to attract top students and faculty to USC as we dramatically expand our presence in the field of structural biology,” said Stephen Bradforth, USC Dornsife divisional dean for Physical Sciences, in the press release.
Source: Thermo Fisher Scientific
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.